Xiaobing Zhang

Xiaobing Zhang

Auto-generated profile, based on publicly available information

Xiaobing Zhang

Division of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SLSijia Liu
Sijia Liu
RGRomán González-Prieto
Román González-Prieto
MZMengdi Zhang
Mengdi Zhang
PGPaul P. Geurink
Paul P. Geurink
RKRaymond Kooij
Raymond Kooij
PDPeter Ten Dijke
Peter Ten Dijke
Purpose: Therapies directed to specific molecular targets are still unmet for patients with triple-negative breast cancer (TNBC). Deubiquitinases (DUB) are emerging drug targets. The identification of highly active DUBs in TNBC may lead to novel therapies. Experimental Design: Using DUB activity probes, we profiled global DUB activities in 52 breast cancer cell lines and 52 patients9 tumor tissues. To validate our findings in vivo, we employed both zebrafish and murine breast cancer xenograft models. Cellular and molecular mechanisms were elucidated using in vivo and in vitro biochemical methods. A specific inhibitor was synthesized, and its biochemical and biological functions were assessed in a range of assays. Finally, we used patient sera samples to investigate clinical correlations. Results: Two DUB activity profiling approaches identified UCHL1 as being highly active in TNBC cell lines and aggressive tumors. Functionally, UCHL1 promoted metastasis in zebrafish and murine breast cancer xenograft models. Mechanistically, UCHL1 facilitates TGFβ signaling–induced metastasis by protecting TGFβ type I receptor and SMAD2 from ubiquitination. We found that these responses are potently suppressed by the specific UCHL1 inhibitor, 6RK73. Furthermore, UCHL1 levels were significantly increased in sera of patients with TNBC, and highly enriched in sera exosomes as well as TNBC cell–conditioned media. UCHL1-enriched exosomes stimulated breast cancer migration and extravasation, suggesting that UCHL1 may act in a paracrine manner to promote tumor progression. Conclusions: Our DUB activity profiling identified UCHL1 as a candidate oncoprotein that promotes TGFβ-induced breast cancer metastasis and may provide a potential target for TNBC treatment.

12 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
XHXiqian Han
Xiqian Han
XZXiaobing Zhang
Xiaobing Zhang
HLHui Li
Hui Li
SHShengshi Huang
Shengshi Huang
SZShu Zhang
Shu Zhang
YSYikang Shi
Yikang Shi
Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo

18 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
HLHanneke Leegwater
Hanneke Leegwater
ZZZhengzheng Zhang
Zhengzheng Zhang
XZXiaobing Zhang
Xiaobing Zhang
THThomas Hankemeier
Thomas Hankemeier
AHAmy Harms
Amy Harms
AKAlida Kindt-Dunjko
Alida Kindt-Dunjko
Sample collection can significantly affect measurements of relative lipid concentrations in cell line panels, hiding intrinsic biological properties of interest between cell lines. Most quality control steps in lipidomic data analysis focus on controlling technical variation. Correcting for the total amount of biological material remains an additional challenge for cell line panels. Here, we investigated how we can normalize lipidomic data acquired from multiple cell lines to correct for differences in sample biomass. We studied how commonly used data normalization and transformation steps during analysis influenced the resulting lipid data distributions. We compared normalization by biological properties such as cell count or total protein concentration, to statistical and data-based approaches, such as median, mean, or probabilistic quotient-based normalization and used intraclass correlation to estimate how similarity between replicates changed after normalization. Normalizing lipidomic data by cell count improved similarity between replicates, but only for a study with cell lines with similar morphological phenotypes. For cell line panels with multiple morphologies collected over a longer time, neither cell count nor protein concentration was sufficient to increase the similarity of lipid abundances between replicates of the same cell line. Data-based normalizations increased these similarities, but also created artifacts in the data caused by a bias towards the large and variable lipid class of triglycerides. This artifact was reduced by normalizing for the abundance of only structural lipids. We conclude that there is a delicate balance between improving the similarity between replicates and avoiding artifacts in lipidomic data and emphasize the importance of an appropriate normalization strategy in studying biological phenomena using lipidomics.

9 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
HLHanneke Leegwater
Hanneke Leegwater
XZXiaobing Zhang
Xiaobing Zhang
LHLuojiao Huang
Luojiao Huang
CHChristine Hoegen
Christine Hoegen
XWXuesong Wang
Xuesong Wang
SDSylvia Emmanuelle Le Dévédec
Sylvia Emmanuelle Le Dévédec
Breast cancer cells undergo metabolic reprogramming to support proliferation and metastasis, but these alterations are heterogeneous. To systematically assess this heterogeneity under controlled conditions, we profiled 31 intracellular polar metabolites and 50 amines, together with exchange rates of 57 amines, in a panel of 51 breast cancer cell lines spanning diverse phenotypes. These data were integrated with lipidomics and transcriptomics. Multi-omics factor analysis identified metabolic signatures linked to proliferation and to differences between luminal, HER2-positive, basal A, and basal B cell lines, overlapping with an epithelial-to-mesenchymal transition phenotype. Fast-proliferating, aggressive cell lines showed increased uptake of essential amino acids and altered nucleotide levels, while heterogeneity in glutamine metabolism was mainly driven the subtype. This was partially associated with heterogeneous expression of metabolite transporters. To test the functional relevance, 67 metabolic genes were silenced in Hs578T using siRNA, and effects on proliferation and migration were measured by a sulforhodamine B assay, live-cell imaging, and a random cell migration assay. This resulted in 34 knockdowns that reduced proliferation and 20 reduced migration, with strong effects for the glycosyltransferases EXT1 and EXT2, nucleotide metabolism genes GART and HPRT1, and metabolite transporters SLC7A1, SLC7A11, and SLC16A3. These findings highlight phenotype-specific metabolic dependencies and identify candidate drug targets in aggressive breast cancer.